Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00603746 · ClinicalTrials.gov registry record · Phase 2
A Randomized Study To Evaluate The Efficacy And Safety Of An Investigational Drug In Adolescent And Adult Subjects With Asthma Uncontrolled on Moderate-Dose ICS Therapy.
A Phase 2 study of Asthma, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 2
- Development phase
- 627
- Enrollment target
- 20
- Study locations
NCT00603746: Completed Phase 2 study of Asthma, sponsored by GlaxoSmithKline.
NCT00603746 is a Phase 2 study of Asthma that has completed, run by GlaxoSmithKline. The registered enrollment target is 627 participants, below the 1,562-participant average among 374 other Asthma trials with a reported enrollment target (60% lower). The trial reports 20 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00603746, a Phase 2 study of Asthma, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 627 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study is designed to determine if the investigational drug is effective and safe in individuals with asthma.
Primary Outcome
Pulmonary function was measured by forced expiratory volume in one second (FEV1), defined as the maximal amount of air that can be forcibly exhaled from the lungs in one second. Pre-dose and pre-rescue bronchodilator (albuterol/salbutamol) trough FEV1 (the measurement of FEV1 performed at the end of the dosing interval) was measured electronically by spirometry in the evening at the Baseline (BL) through Week 8 clinic visits. The highest of 3 technically acceptable measurements was recorded. The
Conditions Studied
Interventions
- DRUG GW685698X
Study Locations (20)
California
- GSK Investigational Site - Fresno
- GSK Investigational Site - Granada Hills
- GSK Investigational Site - Huntington Beach
- GSK Investigational Site - Long Beach
- GSK Investigational Site - Long Beach
- GSK Investigational Site - Los Angeles
- GSK Investigational Site - Los Angeles
- GSK Investigational Site - Palmdale
- GSK Investigational Site - Riverside
- GSK Investigational Site - Roseville
- GSK Investigational Site - San Diego
- GSK Investigational Site - Torrance
- GSK Investigational Site - Walnut Creek
- GSK Investigational Site - West Covina
Arkansas
- GSK Investigational Site - Fort Smith
- GSK Investigational Site - Little Rock
Colorado
- GSK Investigational Site - Colorado Springs
- GSK Investigational Site - Wheat Ridge
Arizona
- GSK Investigational Site - Phoenix
Connecticut
- GSK Investigational Site - Bridgeport
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 627 participants |
| Start Date | 2007-12-01 |
| Est. Completion | 2008-09-20 |
| Phase | Phase 2 |
What the finished NCT00603746 record still lists
NCT00603746 is an interventional study that assigns participants to a tested intervention. The registered 627 participants enrollment target is mid-sized for trials with a published cap, below the 1,562-participant average among 374 other Asthma trials with a reported enrollment target (60% lower).
The record links to 1 condition, with Asthma appearing as the primary indexed condition, and to 1 intervention - of which GW685698X is the first listed.
NCT00603746 names 20 study sites across 5 states, led by California, Arkansas, Colorado.
Frequently Asked Questions
What is clinical trial NCT00603746 about?
NCT00603746 is a clinical study titled "A Randomized Study To Evaluate The Efficacy And Safety Of An Investigational Drug In Adolescent And Adult Subjects With Asthma Uncontrolled on Moderate-Dose ICS Therapy.". This study is designed to determine if the investigational drug is effective and safe in individuals with asthma.
What is the current status of trial NCT00603746?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 627 participants. The study started on 2007-12-01. Estimated completion is 2008-09-20.
What conditions does trial NCT00603746 study?
This clinical trial studies the following conditions: Asthma.
What interventions are being tested in trial NCT00603746?
The interventions under investigation include: GW685698X (DRUG).
Who is sponsoring clinical trial NCT00603746?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00603746 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Asthma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00603746's enrollment target sits among peer trials
627 65th of 374 higher than 310 of 374 other Asthma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Asthma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Escitalopram in Asthma Patients With Frequent Exacerbation
RECRUITING · Phase 2
-
Metformin IN Asthma for Overweight and Obese Individuals (MINA)
RECRUITING · Phase 2
-
Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma
RECRUITING · Phase 2
-
ENV-294 for Moderate-to-Severe Asthma: A 12-Week Study in Adults
RECRUITING · Phase 2
-
A Study to Evaluate Brenipatide Compared With Placebo in Adult Participants With Uncontrolled Moderate to Severe Asthma
RECRUITING · Phase 2
-
Supplementing L-citrulline to Overweight Late Asthma oNset Phenotypes
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06040827 · 626 participants
A Multicenter, Postmarket Surveillance Study of Subjects With the Canary canturioTM te Tibial Extension
- NCT05349227 · 625 participants · NA
Comprehensive Outcomes for After Cancer Health
- NCT06103864 · 625 participants · Phase 3
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer
- NCT06230510 · 625 participants · NA
Milk-Tot Study: Impact of Whole Versus Low-fat Milk on Child Health
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI